Integral Molecular is a research-driven biotechnology company creating innovative technologies and therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, transporters, and viral envelopes.

March 26, 2019

Integral Molecular to Present Claudin 6 MAbs, a Therapeutic Asset for Solid Tumors, at Annual AACR Conference

PHILADELPHIA–Integral Molecular, the industry leader in discovering antibodies against multipass membrane proteins, will showcase updated data on its discovery of highly specific Claudin 6 MAbs at […]
January 7, 2019

Integral Molecular Enters Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo

PHILADELPHIA–(PR NEWSWIRE)–Integral Molecular, the industry leader in membrane protein solutions, today announced that it has entered into a collaboration to discover new therapeutic targets in immuno-oncology […]
January 3, 2019

Integral Molecular Announces Antibody Discovery Collaboration with Ono Pharmaceutical

PHILADELPHIA–(PR NEWSWIRE)–Integral Molecular, the industry leader in the discovery of monoclonal antibodies (MAbs) against multipass membrane proteins, and Ono Pharmaceutical Co., Ltd. today announced that they […]
December 4, 2018

Integral Molecular’s Therapeutic MAbs Against CB1 to Treat NASH Enter New Development Phase Following $1.4M NIH Award

PHILADELPHIA–(PR NEWSWIRE)–Integral Molecular, the industry leader in antibody discovery against multipass membrane proteins, was awarded $1.4M by the NIH to develop its lead antibodies against cannabinoid […]
November 1, 2018

Integral Molecular Awarded NIH Grant to Discover Neuroimmune Drug Targets in Alzheimer’s Disease

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, the industry leader in membrane protein technologies, was awarded a Small Business Innovation Research (SBIR) grant from the NIH to initiate a target […]
September 18, 2018

Integral Molecular Partners with Merus to Discover Novel Therapeutic Monoclonal Antibodies

PHILADELPHIA – (BUSINESS WIRE) – Integral Molecular, the industry leader in the discovery of monoclonal antibodies (MAbs) against membrane proteins, and Merus N.V. (Nasdaq:MRUS), a clinical-stage […]
June 1, 2018

Integral Molecular Celebrates Epitope Mapping Milestone of 1,000 Epitopes

PHILADELPHIA-(BUSINESS WIRE)-Integral Molecular, the industry leader in the discovery and characterization of antibodies against membrane proteins, celebrates a milestone of mapping 1,000 epitopes for customers, collaborators, […]
May 30, 2018

Integral Molecular’s MPS Antibody Discovery Platform Yields Therapeutic Assets for Oncology and Metabolic Syndrome

Integral Molecular, the industry leader in membrane protein antibody discovery, announces the development of antibody assets targeting membrane proteins important in oncology (Claudin 6) and metabolic […]
March 13, 2018

Integral Molecular’s Protein Engineering Technology Facilitates HIV Vaccine Development

PHILADELPHIA–(BUSINESS WIRE)-Integral Molecular, the industry leader in engineering membrane proteins, has extended its protein engineering capabilities to stabilize viral proteins and produce more effective candidate vaccines […]
December 21, 2017

Integral Molecular Expands its Epitope Mapping Platform to Identify Small Molecule Binding Sites on Multipass Membrane Proteins

PHILADELPHIA–(BUSINESS WIRE)– Integral Molecular, the industry leader in the expression and characterization of multipass membrane proteins, has expanded its mapping capabilities to include small molecules. This […]
September 6, 2017

Integral Molecular Hosts Art of Science Residency

PHILADELPHIA (September 6, 2017) – A new kind of interdisciplinary artistic collaboration is happening in Philadelphia this fall. The University City Science Center has partnered with […]
August 30, 2017

Integral Molecular Doubles Antibody Discovery Capacity

PHILADELPHIA-(BUSINESS WIRE)-Integral Molecular, a Philadelphia based biotechnology company, announces the expansion of its facility, personnel, and resources dedicated to antibody discovery for membrane protein targets. The […]
June 15, 2017

Integral Molecular Announces Technology Advancement for Discovery of New Immuno-Oncology Therapeutic Targets

PHILADELPHIA-(BUSINESS WIRE)-Integral Molecular, a leader in membrane protein technologies, has initiated a therapeutic target discovery program in immuno-oncology by exploiting its Membrane Proteome Array technology to […]
June 7, 2017

Integral Molecular Announces the Expansion of its Membrane Proteome Array Technology for Improving Antibody Safety and New Target Discovery

PHILADELPHIA–Integral Molecular announces the expansion of its proprietary Membrane Proteome Array™ to now consist of 5,300 unique human membrane proteins, representing nearly the entire human membrane […]
May 18, 2017

Immunization Elicited Antibody Shows Universal Protection Against Multiple Ebolaviruses

ROCKVILLE, Md., May 18, 2017 /PRNewswire/ — In research published online today in Cell, a team of scientists describe an antibody called CA45, elicited by immunization […]
March 2, 2017

Integral Molecular and Integrated BioTherapeutics Initiate Collaboration for Virus Vaccine Discovery

Philadelphia, PA & Rockville, MD. (BUSINESSWIRE) March 2, 2017 —Integral Molecular and Integrated BioTherapeutics have teamed up in the fight against the global health crises posed […]
November 16, 2016

Integral Molecular Isolates Zika-Specific Monoclonal Antibodies for Vaccine Research and Diagnostics

PHILADELPHIA — Integral Molecular announces the isolation of neutralizing monoclonal antibodies specific for the Zika virus envelope, thereby enabling vital vaccine research and the development of […]
November 7, 2016

Antibody Protects Against Fetal Disease in Mouse Model of Zika Infection

Administering a human antibody that neutralizes Zika virus to pregnant mice before or after Zika virus infection reduced levels of the virus in placental and fetal […]
September 21, 2016

Integral Molecular Launches Target Specificity Technology to Improve Safety of Biotherapeutics

Integral Molecular announces the launch of the Membrane Proteome Array (MPA), a rapid and reliable platform for de-risking therapeutic development by profiling the target specificity of […]
August 25, 2016

Integral Molecular Announces Breakthrough in Understanding the Functionality of GPCRs, the Largest Class of Drug Targets in Human Disease

Philadelphia, PA–(BUSINESS WIRE)–Integral Molecular, an industry leader in membrane protein antibody discovery, has announced a major advancement in understanding the functionality of G protein-coupled receptors (GPCRs), […]